rethinkMushrooms Search
Menu
RethinkMushrooms

Research library — page 5

Browse more mushroom research, methods and limitations.

Filter by topic, method, and evidence

You can select more than one topic or evidence level.

Clear filters

RTHM-01886 · 2024

Chaga Therapeutic Properties: What This 2024 Review Actually Shows

This paper is a broad Chaga field map, not a human clinical review with pooled therapeutic outcomes. The strongest structural move in the article is separating triterpenoids, polysaccharides, phenols or flavonoids, and crude extracts into different evidence buckets instead of flattening them into one Chaga effect. Most of the review's support comes from cell, rodent, and in silico studies, even when the conclusions lean toward treatment language. Several of the liveliest translational claims depend on preparation-specific details such as solvent, extraction method, host-tree contribution, or cultured-versus-wild source. The authors end by acknowledging unresolved questions about food-matrix efficacy and compound or drug interactions, which is a narrower and more defensible conclusion than the headline therapeutic framing. This 2024 review collects a large preclinical Chaga literature across triterpenoids, polysaccharides, phenols, and crude extracts. Its safest takeaway is that Chaga repeatedly hits inflammatory, metabolic, tumor-related, and organ-protective pathways in cells and animals, but the paper does not supply human trials or prove that wild conks, cultured material, and commercial products behave the same way.

Ern, Phoebe Tee Yon; Quan, Tang Yin; Yee, Fung Shin; Yin, Adeline Chia Yoke · Review Article

RTHM-02381 · 2013

Giving obese mice a specific gut bacterium reversed diet-induced fat gain

Administering live Akkermansia muciniphila to high-fat-diet mice reversed fat-mass gain, metabolic endotoxemia, adipose tissue inflammation, and insulin resistance. Heat-killed bacteria produced no benefit, indicating the effect requires viable organisms.

Everard, Amandine; Belzer, Clara; Geurts, Lucie; Ouwerkerk, Janneke P; Druart, Céline; Bindels, Laure B; Guiot, Yves; Derrien, Muriel; Muccioli, Giulio G; Delzenne, Nathalie M; de Vos, Willem M; Cani, Patrice D · Animal Study

RTHM-02282 · 2024

Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017.

In a single-arm phase Ib/II trial (n=33) of Imprime PGG (a 1,3/1,6 beta-glucan) plus pembrolizumab in previously treated advanced NSCLC, the combination was safe (MTD 4 mg/kg) but did not improve outcomes: confirmed objective response rate 10%, median PFS 2.6 months, median OS 11.1 months. Most patients had progressed on prior anti-PD-1/PD-L1 therapy.

Furqan, Muhammad; Malhotra, Jyoti; Shergill, Ardaman; Liu, Lei; Mott, Sarah L; Pasquinelli, Mary M; Hulbert, Alicia; Kennedy, Kelly; Feldman, Lawrence ·